CYP3A was found to play a major role in the drug disposition of drugs approved in 2022, meditating all strong drug interactions.

PBPK was commonly used to evaluate enzyme-mediated DDIs with new drugs as substrates (40%), inhibitors (30%), and inducers (100%).

All transporter-mediated DDIs led to AUCRs below (or close to) 2-fold.

Want to learn more? << Scan Here